J.F. San Miguel

Bortezomib (Velcade)-Melphalan-Prednisone (VMP) Versus Velcade- Thalidomide-Prednisone (VTP) in Elderly Untreated Multiple Myeloma Patients: Which Is the Best Partner for Velcade: An Alkylating or An Immunomodulator Agent?

María‐Victoria Mateos, Albert Oriol, Joaquín Martínez‐López et al. · Blood · 2008 · 30 citations

Medicine, Hematology, Pharmacology +17

Effect of Mesenchymal Stem Cells on the Viability, Proliferation and Differentiation of B Lymphocytes.

Soraya Tabera, José Antonio Pérez‐Simón, María Díez‐Campelo et al. · Blood · 2007 · 14 citations

Life Sciences, Cell Biology, Immunology +11

A Phase I/II National, Multi-Center, Open-Label Study of Bortezomib Plus Melphalan and Prednisone (V-MP) in Elderly Untreated Multiple Myeloma (MM) Patients.

M.V. Mateos, Miguel‐Teodoro Hernández, Joaquín Díaz Mediavilla et al. · Blood · 2005 · 14 citations

Medicine, Hematology, Pharmacotherapy +15

27 Does WBC count really define two different subtypes of chronic myelomonocytic leukemia (CMML)? Analysis of a series of 119 patients

Javier Lizardi Cervera, Guillermo Sanz, T. Valles'i et al. · Leukemia Research · 1997 · 12 citations

Medicine, Hematology, Oncology +13